Analyst consensus rating
X4 Pharmaceuticals Analyst Rating: none
Direct answer
X4 Pharmaceuticals's consensus rating is none.
5 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $11.60.
Forecast evidence checked October 17, 2026.
Get free X4 Pharmaceuticals email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $2.59
- Average price target
- $11.60
- High price target
- $13.00
- Low price target
- $10.00
- Low target gap
- +286.1%
- Target upside
- +347.9%
- High target gap
- +401.9%
- Target range width
- 115.8%
- Consensus rating
- none
- Analysts
- 5
- Evidence date
- October 17, 2026
- Valid through
- October 24, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for X4 Pharmaceuticals?
X4 Pharmaceuticals has a verified none consensus. The same dataset has an average price target of $11.60.
How far are X4 Pharmaceuticals's low and high targets from the recorded price?
The low target implies +286.1%, while the high target implies +401.9%.
How many analysts are included in X4 Pharmaceuticals's consensus?
The verified consensus includes 5 analysts.
How is X4 Pharmaceuticals's target upside or downside calculated?
The average target of $11.60 is divided by the recorded price of $2.59, then one is subtracted to produce +347.9%. This does not guarantee a future return.
When was X4 Pharmaceuticals's analyst forecast verified?
The data was verified on 2026-10-17. The dataset is valid through 2026-10-24.